Biotech Values

[mcbio]

ESPR -

A [Cleveland Clinic] study…involving about 1,600 patients with initial complaints of statin intolerance found that just over 70% could actually take the medicines, while about 30% were truly statin-intolerant.

Would seem to be a negative for at least ESPR if we can take this at face value as that is their primary focus on initial patient population. I think the bigger potential appeal on ESPR is if a big pharma is interested in acquiring their soon Phase 3 ready drug with novel MoA to pair with an existing drug to go after a much broader patient population than statin intolerant. May make sense to wait and see the official guidance from FDA on Phase 3 trial design coming up later this quarter though.